EHR-embedded OCDT in Breast or GI Cancer

Breast Cancer Clinical Trial

Official title: Nonrandomized Phase II Hybrid Type 3 Implementation Study: Feasibility and Acceptance of an EHR-embedded Oral Cancer Directed Therapy Toxicity and Adherence Program for Patients With Breast or Gastrointestinal Cancer

Status Completed

Clinical Trial Summary

This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study is to help researchers better understand gaps in assessing oral chemotherapy patient toxicity at home, adherence to treatment and integrate toxicity/adherence reporting.

Clinical Trial Description

For patients with advanced breast or gastrointestinal cancer prescribed Oral Cancer Directed Therapy.

• Participants will complete ePRO clinic for all medical oncology scheduled provider appointments during the study period per standard practice

• Participants between clinic visits, will be asked to complete the oral weekly survey at home via the mobile or web based patient portal. The survey can be completed on a computer, tablet or smartphone at home or on a tablet at the time of scheduled visit.

• The first 100 participants to complete the survey will receive a passive care team alert for responses (per DFHCC policy)

• The second 100 participants to complete the survey will receive an active care team alert for responses. ;

Related Conditions & MeSH terms

• Breast Cancer
• Gastrointestinal Cancer
• Gastrointestinal Neoplasms
• Mouth Neoplasms
• Oral Cancer Directed Therapy
• Oral Chemotherapy

• NCT number: NCT03858712
• Study type: Interventional
• Source: Dana-Farber Cancer Institute
• Status: Completed
• Phase: N/A
• Start date: March 13, 2019
• Completion date: November 23, 2021